Shionogi Inc v. Cipla USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Shionogi Inc. (Delaware)
  • Defendant: Cipla USA, Inc. (New Jersey) and Cipla Limited (India)
  • Plaintiff's Counsel: FBT Gibbons LLP
• Case Identification: 2:26-cv-09658, D.N.J., 07/30/2026
• Venue Allegations: Venue is alleged to be proper as Cipla USA, Inc. is incorporated in New Jersey with an established place of business, and both defendants have previously consented to venue in the district by litigating other patent disputes. Cipla Limited, as a foreign corporation, may be sued in any judicial district.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's amyotrophic lateral sclerosis (ALS) drug, RADICAVA ORS® (edaravone), constitutes an act of patent infringement under the Hatch-Waxman Act.
• Technical Context: The technology concerns pharmaceutical compositions and methods for administering edaravone, an approved treatment for ALS, specifically focusing on oral suspension formulations and dosing regimens designed to manage the drug's interaction with food.
• Key Procedural History: This action was triggered by Cipla's submission of ANDA No. 218428 and its associated Paragraph IV certification notice, asserting that its proposed generic product would not infringe the patents-in-suit or that the patents are invalid. The complaint notes that Plaintiff Shionogi recently acquired the RADICAVA ORS® business and associated patents from Tanabe Pharma Corporation. The complaint also lists numerous other pending patent infringement actions in the district involving RADICAVA ORS®, indicating a competitive environment for generic entry.

Case Timeline

Date	Event
2018-11-02	'586 Patent Priority Date
2020-11-12	'769 and '469 Patents Priority Date
2022-05-12	FDA approves NDA for RADICAVA ORS®
2024-03-28	FDA grants Orphan Drug Exclusivity for RADICAVA ORS®
2025-12-22	Shionogi announces agreement to acquire RADICAVA ORS® business
2026-01-20	'769 Patent Issue Date
2026-03-10	'469 Patent Issue Date
2026-04-01	Shionogi completes acquisition of RADICAVA ORS® assets
2026-04-14	'586 Patent Issue Date
2026-06-15	Cipla sends Notice Letter regarding its ANDA filing
2026-07-30	Complaint Filing Date

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,527,769 - "Pharmaceutical composition for oral administration of edaravone and method of administering same"

• Patent Identification: U.S. Patent No. 12,527,769, issued January 20, 2026. Compl. ¶37

The Invention Explained

• Problem Addressed: The patent addresses the problem that the absorption and pharmacokinetic profile of orally administered edaravone, a treatment for the neurodegenerative disease ALS, are negatively affected by food consumption. U.S. Patent No. 12,527,769, col. 16:40-49 This "food effect" can reduce the drug's concentration in the blood and potentially its therapeutic efficacy.
• The Patented Solution: The patent claims a method for administering edaravone that avoids this negative food effect by specifying mandatory waiting periods between eating and taking the drug, with the length of the waiting period depending on the type of meal consumed (high-fat, standard, or light). '769 Patent, abstract This timed administration is intended to achieve a pharmacokinetic profile (e.g., maximum concentration (Cmax) and total exposure (AUC)) similar to that achieved when the drug is taken in a fasted state. '769 Patent, col. 15:15-30 The patent provides graphical data comparing drug concentration after meals with and without the claimed waiting periods. For example, a spaghetti plot in the patent illustrates the variability of Cmax under different meal conditions. '769 Patent, Fig. 1
• Technical Importance: This method provides a predictable dosing regimen that allows patients to receive the therapeutic benefits of oral edaravone without the significant logistical burden and clinical variability associated with the food effect. '769 Patent, col. 16:50-65

Key Claims at a Glance

• The complaint asserts at least Independent Claim 1. Compl. ¶48
• Claim 1 of the '769 Patent recites the essential elements of:
  • A method of treating amyotrophic lateral sclerosis.
  • The method comprises orally or intragastrically administering a liquid pharmaceutical composition that includes edaravone.
  • The administration occurs after a "first time interval" from the consumption of a meal.
  • The first time interval is defined as 8 hours for a high-fat meal, 4 hours for a low-fat meal, or 2 hours for a caloric supplement.
  • Practicing the method results in a decrease in Cmax of less than 20% and/or a decrease in AUC of less than 10% compared to administration in a fasted state. '769 Patent, claim 1
• The complaint does not explicitly reserve the right to assert dependent claims but alleges infringement of "one or more claims." Compl. ¶48

U.S. Patent No. 12,569,469 - "Pharmaceutical composition for oral administration of edaravone and method of administering same"

• Patent Identification: U.S. Patent No. 12,569,469, issued March 10, 2026. Compl. ¶38

The Invention Explained

• Problem Addressed: Similar to the '769 Patent, this patent addresses the negative effect of food consumption on the pharmacokinetics of oral edaravone. U.S. Patent No. 12,569,469, col. 16:40-49
• The Patented Solution: This patent builds on the solution in the '769 Patent by claiming a method that specifies not only a "first time interval" before drug administration but also a "second time interval" after drug administration, during which the patient must wait before consuming their next meal. '469 Patent, abstract '469 Patent, claim 1 The claimed method requires waiting at least one hour after taking the drug before eating again. '469 Patent, claim 1 This two-part timing regimen is intended to further ensure that the drug's absorption is not impacted by food.
• Technical Importance: By defining both pre- and post-administration fasting periods, the method aims to provide an even more robust and reliable dosing schedule to maximize drug absorption and therapeutic effect, independent of a patient's meal schedule. '469 Patent, col. 29:8-16

Key Claims at a Glance

• The complaint asserts at least Independent Claim 1. Compl. ¶59
• Claim 1 of the '469 Patent recites the essential elements of:
  • A method of treating amyotrophic lateral sclerosis.
  • The method comprises orally or intragastrically administering a liquid pharmaceutical composition including edaravone.
  • The administration occurs after a "first time interval" from a prior meal (8 hours for high-fat, 4 hours for low-fat, 2 hours for caloric supplement).
  • The method also requires a "second time interval" of 1 hour from administration to the consumption of the next meal. '469 Patent, claim 1
• The complaint alleges infringement of "one or more claims." Compl. ¶59

U.S. Patent No. 12,599,586 - "Edaravone suspension for oral administration"

• Patent Identification: U.S. Patent No. 12,599,586, issued April 14, 2026. Compl. ¶39
• Technology Synopsis: This patent addresses the technical challenges of creating a stable, effective, and bioavailable oral liquid formulation of edaravone. It claims a specific pharmaceutical suspension comprising edaravone particles of a particular size range, a dispersant to keep the particles suspended in water, and a defined dissolution rate, which together ensure proper delivery of the active ingredient. U.S. Patent No. 12,599,586, abstract '586 Patent, claim 1
• Asserted Claims: The complaint asserts at least Independent Claim 1. Compl. ¶70
• Accused Features: The complaint alleges that Cipla's proposed "edaravone suspension" product itself, as described in its ANDA, infringes the claims of the '586 patent. Compl. ¶41 Compl. ¶43 Compl. ¶70

III. The Accused Instrumentality

Product Identification

The accused instrumentality is Defendants' proposed generic edaravone oral suspension product, which is the subject of ANDA No. 218428. Compl. ¶21

Functionality and Market Context

• The complaint alleges that Cipla's product is a generic copy of the branded drug RADICAVA ORS® and is intended for the treatment of ALS. Compl. ¶21 Compl. ¶43 It is described as an "edaravone suspension, administered at a dose concentration of 105 mg/5 mL." Compl. ¶41 As a generic equivalent, it is designed to have the same active ingredient, dosage form, strength, and route of administration as RADICAVA ORS® and to be bioequivalent. Compl. ¶40 Compl. ¶42
• The complaint highlights the market importance of RADICAVA ORS® as one of only a few approved treatments for ALS and notes its clinical superiority over a prior intravenous formulation due to the convenience of oral administration at home. Compl. ¶8 Compl. ¶11 The filing of an ANDA suggests Defendants' intent to compete in this market upon receiving FDA approval. Compl. ¶27

IV. Analysis of Infringement Allegations

U.S. Patent No. 12,527,769 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating amyotrophic lateral sclerosis, comprising: orally or intragastrically administering, to a subject in need thereof, a liquid pharmaceutical composition comprising edaravone...	The proposed product is an oral edaravone suspension intended for treating ALS. The proposed labeling is alleged to instruct or encourage this administration.	¶41; ¶49	col. 45:1-10
...with a first time interval from a consumption of a meal by the subject in need thereof to an administration of the liquid pharmaceutical composition to the subject in need thereof, wherein the first time interval for the consumption of a high-fat meal... is 8 hours..., the first time interval for the consumption of a low-fat meal... is 4 hours..., or the first time interval for the consumption of a caloric supplement... is 2 hours...	The proposed product label is alleged to instruct physicians and patients to administer the generic edaravone suspension according to these specific time intervals relative to meal type.	¶49	col. 45:11-28
...such that a decrease in Cmax is less than 20% with respect to Cmax in a same time range in fasting for 10 hours or longer and/or that a decrease in AUC is less than 10% with respect to AUC in a same time range in fasting for 10 hours or longer.	By following the proposed label's instructions, users will allegedly achieve a pharmacokinetic profile (Cmax and AUC) for the generic product that is bioequivalent to the branded product and meets the claimed criteria relative to a fasted state.	¶40; ¶48	col. 45:29-46:10

U.S. Patent No. 12,569,469 Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method of treating amyotrophic lateral sclerosis, comprising: orally or intragastrically administering, to a subject in need thereof, a liquid pharmaceutical composition comprising edaravone...	The proposed product is an oral edaravone suspension for treating ALS. The proposed labeling is alleged to instruct this administration.	¶41; ¶60	col. 43:6-12
...with a first time interval from a consumption of a meal by the subject in need thereof... wherein the first time interval... is 8 hours..., the first time interval... is 4 hours..., or the first time interval... is 2 hours...	The proposed product label is alleged to instruct users to follow these specific pre-administration waiting periods based on meal type.	¶60	col. 45:3-12
...and a second time interval from the administration of the liquid pharmaceutical composition to the consumption of the next meal by the subject in need thereof is 1 hour.	The proposed product label is alleged to instruct users to wait at least 1 hour after taking the drug before consuming their next meal.	¶60	col. 45:12-24

Identified Points of Contention

• Scope Questions (Method Claims): A central dispute for the '769 and '469 patents will likely be whether Cipla's proposed product label instructs or encourages administration in a way that meets every limitation of the claimed methods. This raises the question of whether Cipla can design a label that "carves out" the patented methods of use to avoid inducing infringement, a common strategy in ANDA litigation.
• Technical Questions (Formulation Claim): For the '586 patent, the dispute will be a factual comparison of Cipla's proposed formulation against the claim limitations. This raises the evidentiary question of whether Cipla's suspension uses edaravone particles of the claimed size and achieves the claimed dissolution rate, which will require discovery and expert analysis of the ANDA product.
• Definitional Questions (Method Claims): The infringement analysis for the method claims may turn on how terms like "high-fat meal" and "low-fat meal" are construed. The patents provide specific caloric and composition definitions for these terms '769 Patent, col. 18:30-40, and a key question will be whether the instructions on Cipla's proposed label are specific enough to fall squarely within those definitions.

V. Key Claim Terms for Construction

For U.S. Patent Nos. 12,527,769 and 12,569,469:

• The Term: "high-fat meal"
• Context and Importance: This term is critical because it triggers the longest and most burdensome waiting period (8 hours) in the claimed methods. The scope of what constitutes a "high-fat meal" directly impacts the frequency with which patients would be required to follow this specific instruction, and therefore is central to the infringement analysis. Practitioners may focus on this term to determine if the instructions on a generic label would be specific enough to induce infringement of this limitation.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification states that meals can be classified "based on common classification criteria," which may suggest the term is not strictly limited to the patent's own examples. '769 Patent, col. 18:5-7 The patent also notes the term can include a meal described as "the high-fat meal in the FDA guideline," potentially incorporating external standards by reference. '769 Patent, col. 18:45-49
  • Evidence for a Narrower Interpretation: The specification provides a very specific definition: "total calories per meal of 800 to 1000 kilocalories, and examples include a meal with... calorie intake from lipid of 50%." '769 Patent, col. 18:30-33 A party could argue that this explicit definition limits the claim to meals meeting these specific caloric and fat-content thresholds.

VI. Other Allegations

• Indirect Infringement: The complaint explicitly alleges active inducement of infringement under 35 U.S.C. § 271(b). The factual basis is the allegation that Cipla's proposed product labeling and package insert will "instruct, encourage, and/or promote" administration by physicians and patients in a manner that directly practices the methods claimed in the '769 and '469 patents. Compl. ¶49 Compl. ¶60
• Willful Infringement: The complaint alleges that Cipla was aware of the patents-in-suit prior to filing its ANDA certification. It further alleges that Cipla proceeded with its ANDA filing despite an "objectively high likelihood that its submission constituted infringement of a valid patent," and that this risk was either known or "so obvious that it should have been known." Compl. ¶53 Compl. ¶64 Compl. ¶74 This pleading seeks to establish the basis for enhanced damages under 35 U.S.C. § 285.

VII. Analyst's Conclusion: Key Questions for the Case

1. A question of inducement and label carve-out: The central issue for the method-of-use patents ('769 and '469) will be whether the language in Cipla's final, FDA-approved label will be found to actively instruct or encourage administration in a way that maps directly onto the patents' specific meal- and time-based limitations, or if Cipla can successfully "carve out" the patented methods to avoid liability for indirect infringement.

2. A technical question of formulation equivalence: The core of the dispute over the formulation patent ('586) will be a factual and technical one: does Cipla's proposed edaravone suspension, as detailed in its confidential ANDA submission, possess the specific physical and chemical properties-such as particle size, dispersant type, and dissolution rate-that are explicitly required by the asserted claims?

3. A definitional question of claim scope: The outcome may also depend on claim construction, particularly how the court defines the different meal types (e.g., "high-fat meal"). A narrow construction tied strictly to the patent's specific caloric examples could make it more difficult for the plaintiff to prove that a generic drug label with more general instructions induces infringement.